Warning letter
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.: warning letter of Jul 9, 2014
FDA warning letter 417081 · Center for Drug Evaluation and Research
Key facts
| Reference number | 417081 |
|---|---|
| Company | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Jul 9, 2014 |
| Posted date | Jul 29, 2014 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 201.1(h)(2) |
| Inspection city | Taizhou |
| Inspection start date | Oct 21, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: